Digital medicine company Akili raised more than $163 million by combining with public trade acquisition company Capital Survetta Holdings.
Akili created EndeavorRx, the first FDA-cleared prescription treatment video game, according to an Aug. 19 news release from the company. The digital therapeutic program is designed to help treat pediatric attention deficit hyperactivity disorder.
The company expects EndeavorRx to expand to treat a wider range of conditions, including autism spectrum disorder, multiple sclerosis and major depressive disorder.
"I am proud of our talented employees — leaders in neuroscience, entertainment and consumer technology — who are propelling Akili's innovative software-based therapeutics forward to deliver an engaging, immersive experience," Eddie Martucci, PhD, CEO of Akili, said in the release.
The software is expected to launch in the fourth quarter of this year.